The China Food and Drug Administration (CFDA) has been changing how medical devices are regulated by expanding and updating their laws. They have released multiple draft documents which elaborate on the caliber of medical device clinical trials and devices that may be exempt from this. The CFDA hopes that the guidance documents can prepare regulatory staff members and create more efficiency within the system. The on-site inspection documents were open to feedback until the 27th of May. Meanwhile, feedback for the document detailing devices exempt from medical clinical trials is due by June the 20th. The CFDA’s overhaul of regulatory affairs is in response to China’s increasingly growing and global industry.

More details can be found in this article.

RegDesk is an A.I.-powered regulatory intelligence software that offers 24/7 access to the latest regulatory information for over 50 markets worldwide. Our platform eliminates the need for medical device companies to spend months gathering intelligence and preparing their registration applications. Through RegDesk’s centralized platform, clients can get access to product-specific registration requirements, expert answers to their most critical regulatory questions, and real-time alerts about global regulatory changes. To experience the power of RegDesk, contact us at or visit